The gastrin-releasing peptide receptor (GRPR) has attracted much attention in nuclear oncology owing to its high-density expression in frequently occurring human cancers, such as prostate cancer, mammary carcinoma, and others [1,2,3,4,5,6,7]. Here, GRPR is linked to prostate carcinoma.